for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PerkinElmer, Inc.

PKI

Latest Trade

143.56USD

Change

2.29(+1.62%)

Volume

763,902

Today's Range

141.23

 - 

144.43

52 Week Range

88.60

 - 

162.70

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
141.27
Open
141.98
Volume
763,902
3M AVG Volume
21.00
Today's High
144.43
Today's Low
141.23
52 Week High
162.70
52 Week Low
88.60
Shares Out (MIL)
112.09
Market Cap (MIL)
16,091.81
Forward P/E
15.08
Dividend (Yield %)
0.20

Next Event

PerkinElmer Inc Virtual Investor and Analyst Day

Latest Developments

More

Perkinelmer Expands Cell Biology Leadership With Agreement To Acquire Nexcelom Bioscience

Perkinelmer Sees FY Revenue $4.37 Billion

Perkinelmer Inc - Anticipates Reported And Organic Revenue Growth Of 98% And 90%, Respectively, For Q1

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PerkinElmer, Inc.

PerkinElmer Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. Its Discovery & Analytical Solutions segment serves the life sciences and applied markets. Through the Diagnostics Segment, it offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals. It provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its product under various brands, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, FragilEase, Genoglyphix, GSP, PG-Seq, PG-Find, Protein Clear, ProteinEXact and QSight, Glutomatic, Honigs Regression, HyperDSC, Inframatic, LAMBDA, NexION, NEN, OneSource, Opera Phenix, Operetta CLS and OsteoSense.

Industry

Scientific & Technical Instr.

Contact Info

155 Federal St Ste 700

BOSTON, MA

02110-1727

United States

+1.781.6635776

http://www.perkinelmer.com/

Executive Leadership

Alexandros P. Michas

Independent Non-Executive Chairman of the Board

Prahlad R. Singh

President, Chief Executive Officer, Director

James M. Mock

Chief Financial Officer, Senior Vice President

Joel S. Goldberg

Senior Vice President - Administration, General Counsel, Secretary

Daniel R. Tereau

Senior Vice President, Strategy and Business Development

Key Stats

2.25 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

2.8K

2019

2.9K

2020

3.8K

2021(E)

4.4K
EPS (USD)

2018

3.610

2019

4.100

2020

8.300

2021(E)

9.518
Price To Earnings (TTM)
15.03
Price To Sales (TTM)
3.63
Price To Book (MRQ)
4.02
Price To Cash Flow (TTM)
12.10
Total Debt To Equity (MRQ)
64.42
LT Debt To Equity (MRQ)
55.46
Return on Investment (TTM)
16.65
Return on Equity (TTM)
14.18

Latest News

Latest News

PerkinElmer forecasts 12% rise in second-quarter revenue

Diagnostic kit maker PerkinElmer Inc <PKI.N> on Monday forecast a 12% rise in second-quarter revenue on better-than-expected demand for its COVID-19 testing products.

Exclusive: U.S. probes PerkinElmer's role in massive Medicare fraud - sources

Medical diagnostic firm PerkinElmer Inc faces a federal investigation into its role in an alleged Medicare fraud involving tens of thousands of unnecessary genetic cancer tests, according to three sources with knowledge of the probe and documents reviewed by Reuters.

BRIEF-PerkinElmer Says Got Subpoenas From Government Regarding Investigations Into Third Parties

* PERKINELMER - GOT SUBPOENAS FROM GOVERNMENT REGARDING INVESTIGATIONS INTO THIRD PARTIES Source text for Eikon: Further company coverage:

BRIEF-Perkinelmer Reports Q1 Adj EPS Of $0.67 From Continuing Operations

* PERKINELMER ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2020

BRIEF-FDA Provides Emergency Use Authorization To Perkinelmer For Serological Test To Identify Covid-19 Antibodies

* FDA PROVIDES EMERGENCY USE AUTHORIZATION TO PERKINELMER FOR SEROLOGICAL TEST TO IDENTIFY COVID-19 ANTIBODIES

BRIEF-Perkinelmer Approved A Modification To Director Compensation Program

* PERKINELMER - ON MARCH 30, BOARD APPROVED A MODIFICATION TO THE COMPANY’S DIRECTOR COMPENSATION PROGRAM

BRIEF-Perkinelmer Says Has Expanded Production Capacity Of Its New Coronavirus RT-PCR Tests

* PERKINELMER - HAS EXPANDED PRODUCTION CAPACITY OF ITS EXTRACTION AND NEW CORONAVIRUS RT-PCR TESTS AT ITS GLOBAL FACILITIES - SEC FILING Source text: [https://bit.ly/2QO7Yh4] Further company coverage:

BRIEF-FDA Provides Emergency Use Authorization To Perkinelmer For Covid-19 Testing

* FDA PROVIDES EMERGENCY USE AUTHORIZATION TO PERKINELMER FOR COVID-19 TESTING

BRIEF-PerkinElmer Expects Q1 Revenue And EPS To Be Below Previous Guidance

* PERKINELMER - EXPECTS Q1 2020 REVENUE AND EARNINGS PER SHARE, BOTH ON A GAAP AND NON-GAAP BASIS, TO BE BELOW COMPANY'S PREVIOUSLY COMMUNICATED GUIDANCE

BRIEF-PerkinElmer Elects Michel Vounatsos To Its Board Of Directors

* PERKINELMER ELECTS MICHEL VOUNATSOS TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up